Loading...

Haleon plc

HLNCF•PNK
HealthcareDrug Manufacturers - Specialty & Generic
$5.64
$0.23(4.16%)

Haleon plc (HLNCF) Stock Overview

Explore Haleon plc’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-0.61%
↓ 0.61%
Profit Growth
$0.16
↑ 37.46%
EPS Growth
$0.16
↑ 45.45%
Operating Margin
19.64%
↑ 10.52%
ROE
8.73%
↑ 37.46%
Dividend Yield
0.00%
↑ 49.43%
Analyst Recommendations data is not available for HLNCFAnalyst Recommendations details for HLNCF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

CEO

Mr. Brian James McNamara

Employees

24,561

Headquarters

Building 5, Weybridge

Founded

2022

Frequently Asked Questions